Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report

被引：4

作者：

Okazaki, Kosuke ^{[1
]}

Yamamuro, Kazuhiko ^{[1
]}

Iida, Junzo ^{[2
]}

Kishimoto, Toshifumi ^{[1
]}

机构：

[1] Nara Med Univ, Sch Med, Dept Psychiat, 840 Shijo Cho, Kashihara, Nara 6348521, Japan

[2] Nara Med Univ, Sch Med, Fac Nursing, Kashihara, Nara, Japan

来源：

ANNALS OF GENERAL PSYCHIATRY | 2019年 / 18卷 / 1期

基金：

日本学术振兴会;

关键词：

Guanfacine; Atomoxetine; Methylphenidate; Attention deficit; hyperactivity disorder; Autism spectrum disorder; Tourette syndrome; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; RAT PREFRONTAL CORTEX; EXTENDED-RELEASE; EXTRACELLULAR DOPAMINE; LONG-TERM; CHILDREN; EFFICACY; NORADRENALINE; ADOLESCENTS;

D O I：

10.1186/s12991-019-0226-6

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

BackgroundPatients with attention deficit/hyperactivity disorder (ADHD) often experience comorbid conditions, such as autism spectrum disorder (ASD) and Tourette syndrome (TS). Although pharmacotherapies are effective for treating ADHD, they are likely to elicit a variety of adverse effects. It is, thus, important to select an effective and well-tolerated pharmacotherapeutic treatment for patients with ADHD/ASD comorbid with TS.Case presentationWe report the case of a 10-year-old boy with ADHD/ASD comorbid with TS who was treated with guanfacine (GUAN). He experienced several side effects of atomoxetine (ATX) and methylphenidate (MPH) before being treated with GUAN. In the presented case, symptoms of ADHD as well as tic symptoms were improved by treatment with GUAN.ConclusionGUAN might be effective and well tolerated in the treatment of patients with ADHD/ASD comorbid with TS who experience side effects of ATX and MPH.

引用

页数：5

共 38 条

[31] Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine [J].

Tanda, G ;

Pontieri, FE ;

Frau, R ;

DiChiara, G .

EUROPEAN JOURNAL OF NEUROSCIENCE, 1997, 9 (10) :2077-2085

[32] European clinical guidelines for hyperkinetic disorder -: first upgrade [J].

Taylor, E ;

Döpfner, M ;

Sergeant, J ;

Asherson, P ;

Banaschewski, T ;

Buitelaar, J ;

Coghill, D ;

Danckaerts, M ;

Rothenberger, A ;

Sonuga-Barke, EJS ;

Steinhausen, HC ;

Zuddas, A .

EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2004, 13 (Suppl 1) :7-30

[33] Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate [J].

Volkow, ND ;

Wang, GJ ;

Fowler, JS ;

Gatley, SJ ;

Logan, J ;

Ding, YS ;

Hitzemann, R ;

Pappas, N .

AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (10) :1325-1331

[34] Methylphenidate-Elicited Dopamine Increases in Ventral Striatum Are Associated with Long-Term Symptom Improvement in Adults with Attention Deficit Hyperactivity Disorder [J].

Volkow, Nora D. ;

Wang, Gene-Jack ;

Tomasi, Dardo ;

Kollins, Scott H. ;

Wigal, Tim L. ;

Newcorn, Jeffrey H. ;

Telang, Frank W. ;

Fowler, Joanna S. ;

Logan, Jean ;

Wong, Christopher T. ;

Swanson, James M. .

JOURNAL OF NEUROSCIENCE, 2012, 32 (03) :841-849

[35] α2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex [J].

Wang, Min ;

Ramos, Brian P. ;

Paspalas, Constantinos D. ;

Shu, Yousheng ;

Simen, Arthur ;

Duque, Alvaro ;

Vijayraghavan, Susheel ;

Brennan, Avis ;

Dudley, Anne ;

Nou, Eric ;

Mazer, James A. ;

McCormick, David A. ;

Arnsten, Amy F. T. .

CELL, 2007, 129 (02) :397-410

[36] Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults [J].

Wigal, Sharon B. .

CNS DRUGS, 2009, 23 :21-31

[37]

Yamamoto BK, 1998, J NEUROCHEM, V71, P274

[38] The clinical necessity for assessing Attention Deficit/Hyperactivity Disorder (AD/HD) symptoms in children with high-functioning Pervasive Developmental Disorder (PDD) [J].

Yoshida, Y ;

Uchiyama, T .

EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2004, 13 (05) :307-314

← 1 2 3 4 →